Butyric Acid

Butyric Acid

SCHEMBL1307932

CCCC(=O)O.O=C(OC1(c2ccccc2)CNC1)C(F)(F)F

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 8/20 0.35
OPRD1 P41143 4/20 0.34
OPRK1 P41145 4/20 0.34
DRD3 P35462 1/20 0.33
OPRL1 P41146 2/20 0.33
FFAR3 O14843 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
P2RY14 Q15391 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1310036 0.88 CES1 (0.35) OPRM1OPRD1OPRK1
Trifluoroacetic Acid SCHEMBL1309725 0.84 OPRM1 (0.40) OPRM1OPRD1OPRK1DRD3OPRL1
SCHEMBL21523860 0.78 P2RY14 (0.40) OPRM1OPRD1OPRK1P2RY14
SCHEMBL27846025 0.77 ELANE (0.41) OPRM1OPRD1OPRK1
SCHEMBL17080483 0.74 TRPV1 (0.31) P2RY14
Trifluoroacetic Acid SCHEMBL1309634 0.74 DRD2 (0.39) OPRM1DRD3OPRL1
Trifluoroacetic Acid SCHEMBL15212228 0.73 P2RY14 (0.38) OPRM1OPRD1OPRK1OPRL1P2RY14
Trifluoroacetic Acid SCHEMBL1312432 0.72 CYP2C9 (0.39) OPRM1OPRD1OPRK1OPRL1
SCHEMBL24944598 0.67 OPRM1 (0.51) OPRM1OPRD1OPRK1DRD3OPRL1
SCHEMBL27894690 0.67 HTR2A (0.42) OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8877968-B2 Melanocortin receptor modulators, process for preparing them and use there in human medicine and cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2014-11-04 US disclosed
EP-2352728-B1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS GALDERMA RES & DEV (FR) 2014-05-21 EP disclosed
US-20110275657-A1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2011-11-10 US disclosed
EP-2352728-A1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS Galderma Research & Development (FR) 2011-08-10 EP disclosed
WO-2010052255-A1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275657-A1 MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THERE IN HUMAN MEDICINE AND COSMETICS MC1R, MC5R, MC3R OPRM1 69/4885OPRD1 263/4885OPRK1 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.